Samsung Biologics posts record 2024 sales, operating profit as it goes global
South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating p...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
Samsung Biologics signs initial deal with LigaChem Bio on ADC production
Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences I...
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
Samsung invests in BrickBio in US
Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technol...
Samsung Biologics signs ADC CDO deal with LegoChem Bio
Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...
Celltrion, WuXi XDC to develop new antibody-drug conjugates
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...
Lotte Biologics, NJ Bio to jointly develop ADC
South Korea's Lotte Biologics Co. announced on Monday that it has signed a strategic business agreement with NJ Bio, a US-based preclinical and clin...
LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal
LegoChem Biosciences Inc. has signed a blockbuster $1.7 billion deal to license out its proprietary antibody drug conjugate (ADC) candidate to Jasse...
SK Pharmteco secures 12 global pharma clients, sets up US R&D center
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has secured 12 global pharm...
Samsung Biologics to double production by 2032; eyes ADCs, M&As
BOSTON – Samsung Biologics Co., the world’s No. 1 contract drugmaker, plans to more than double its total annual production capacity to ...
Lotte Biologics invests in S.Korean bio-venture Pinotbio
South Korea’s Lotte Biologics Co. said on Friday that it has made an equity investment in Pinotbio, Inc. for the development of antibody-drug ...
Chong Kun Dang, Synaffix ink deal to introduce ADC technology
Chong Kun Dang Pharmaceutical Corp. said on Monday that it has signed a contract with Dutch biotechnology firm Synaffix B.V for the use of antibody-...
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Samjin Pharm to undertake joint ADC R&D with Novelty Nobility
SamjinPharmaceutical announced Wednesday that it has signed a joint research agreement with Novelty Nobility Inc., a company specializing in antibod...
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Celltrion looks beyond biosimilars to develop its own mRNA drugs
South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...
LegoChem’s biotech platform drives 28% share price spike over last month
The rise of the platform economy is a global phenomenon. The spread of the coronavirus pandemic has accelerated the use of contactless technology an...
